MedImmune establishes new R&D facility in Cambridge, UK

The Aaron Klug Building is a 92,000sqft facility containing laboratories. The facility provides MedImmune with capacity to significantly increase the number of candidate drugs that it can develop each year in order to meet R&D goals.

According to the company, the Aaron Klug Building is a major expansion of MedImmune’s existing Granta Park site, further cements the region as a major R&D center for the company, and provides additional laboratory space for MedImmune’s growing scientific staff in Cambridge.

Jane Osbourn, site leader and vice president of research, Cambridge, said: “Today, MedImmune has one of the largest and most diverse biologics product pipelines in the biotech and pharmaceutical industries. We want to maximize our potential to develop new and better medicines, so adequate space and resource for R&D is a real priority for us.

“Our experience and expertise in Cambridge means the UK team plays a central role in MedImmune’s global research activity. The Aaron Klug Building is critical to allowing us to fulfill this role and to achieve our goal of significantly increasing our drug development capabilities.”